EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WATERTOWN, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint reported top-line data on two phase 2 trials for its lead pipeline candidate. The company focuses on serious eye disorders.

Why Shares of EyePoint Pharmaceuticals Were Rising Monday

- Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related ocular or systemic serious adverse events in Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy -

EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023

WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that the Company will participate at the following upcoming conferences:

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

EyePoint Pharmaceuticals is developing the EYP-1901 treatment for wet age-related macular degeneration and non-proliferative diabetic retinopathy. Q2 2023 earnings show a decrease in net revenue, but the company has a strong cash position to fund operations until 2025. EYP-1901 shows promise, but potential risks exist. Phase 2 trial data expected in December 2023 and Q2 2024 will provide a more comprehensive assessment.

EyePoint: Well-Funded And Catalyst-Rich, But Not Without Risks

WATERTOWN, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Jay S. Duker, M.D., President and Chief Executive of EyePoint Pharmaceuticals will present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference:

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q2 2023 Earnings Call Transcript August 2, 2023 8:30 AM ET Company Participants George Elston - Chief Financial Officer Dr. Jay Duker - President, and Chief Executive Officer Conference Call Participants Tyler Van Buren - Cowen Yatin Suneja - Guggenheim Jennifer Kim - Cantor Fitzgerald Colleen Kusy - Baird Daniel Catalin - Chardan Sean Kim - Jones Trading I-Eh Jen - Laidlaw & Co Chaitanya Gollakota - H.C. Wainwright Operator Good morning.

EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2023 Earnings Call Transcript

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of $0.41. This compares to loss of $0.52 per share a year ago.

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Lags Revenue Estimates

–Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration remains on track to report topline data in December 2023 –

EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments

Interim safety data from the Phase 2 DAVIO 2 trial continues to demonstrate EYP-1901 is well tolerated with no reported drug-related ocular or systemic SAEs

EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit

WATERTOWN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 2, 2023 to report its second quarter 2023 financial results and highlight recent corporate developments.

EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023

– Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer –

EyePoint Pharmaceuticals Announces Chief Executive Officer Transition

– Significant investigator and patient interest drove strong recruitment of 77 patients exceeding the 60 patient target –

EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy

WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that George Elston, Chief Financial Officer of EyePoint Pharmaceuticals, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 2:30 p.m. ET.

EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference

EyePoint is a $200m market cap biotech focused on eye disease. The company's long-acting Durasert technology has been supporting its commercial product, YUTIQ, which earned $28m of revenues in FY22. EyePoint recently announced however that it had sold YUTIQ to Alimera Sciences for $75m upfront plus $30m in instalments, and royalties on net sales.

EyePoint Pharmaceuticals: A Puncher's Chance For Long Acting Eye Disease Drug Success

–$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt retired and expected cash runway extended into 2025 – EyePoint well-capitalized beyond key EYP-1901 Phase 2 DAVIO 2 and PAVIA clinical trial inflection points WATERTOWN, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that it has entered into a definitive agreement for the sale of YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences, Inc. (“Alimera”).

EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2023 Results Conference Call May 3, 2023 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - Chief Executive Officer Dr. Jay Duker - President and Chief Operating Officer Scott Jones - Chief Commercial Officer Conference Call Participants Yatin Suneja - Guggenheim Tyler Van Buren - Cowen Jennifer Kim - Cantor Fitzgerald Colleen Kusy - Baird Daniel Catalin - Chardan I-Eh Jen - Laidlaw & Co Chaitanya Gollakota - H.C. Wainwright Julian Harrison - BTIG Operator Good morning.

EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2023 Earnings Call Transcript

– Completed enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration (AMD); topline data anticipated in 4Q 2023

EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments

WATERTOWN, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 3, 2023 to report its first quarter 2023 financial results and highlight recent corporate developments.

EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023

EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?

- Significant investigator and patient interest drove strong recruitment, exceeding enrollment goals

EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD

- Positive neuroprotective effect of vorolanib, the active drug in EYP-1901, in a widely validated retinal detachment model demonstrates a potential new mechanism of action for the treatment of retinal disease -

EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

EyePoint Pharmaceuticals (EYPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -32.42% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Nancy Lurker - CEO George O. Elston - CFO Jay Duker - President and COO Scott Jones - Chief Commercial Officer Conference Call Participants Unidentified Analyst - Guggenheim Securities Georgi Yordanov - Cowen Jennifer Kim - Cantor Fitzgerald Yale Jen - Laidlaw & Company Yi Chen - H.C.

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2022 Earnings Call Transcript

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 3.17% and 8.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

News for EyePoint Pharmaceuticals Stock (EYPT)